Speeches and presentations

Axel Hoos, Senior Vice-President Oncology R&D, hosted a Fireside Chat at the Guggenheim Healthcare Talks Idea Forum, Oncology Day, held in New York City on Thursday, February 13th, during which he provided an update on GSK Oncology R&D progress.

Emma Walmsley, CEO, presented at the 38th annual JP Morgan Healthcare Conference in San Francisco on Tuesday 14 January, and provided an overview of GSK’s priorities and the progress the company made during 2019.  The presentation was followed by a Q&A session. 

On Tuesday, 17 December 2019 at 17:00 GMT / 12:00 EST, Hal Barron, Chief Scientific Officer and President of R&D, Luke Miels, President Pharmaceuticals and Axel Hoos, SVP Oncology R&D hosted an investor/analyst conference call to discuss GSK’s pivotal DREAMM-2 data on belantamab mafodotin (GSK’916).

On Monday, 30 September 2019, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of the PRIMA data on Zejula (niraparib) and the INDUCE-1 data on GSK’609 (ICOS) at the 2019 European Society for Medical Oncology (ESMO) congress. The call also featured participation from an external expert in ovarian cancer and other GSK senior oncology leaders.

Roger Connor, President, GSK Vaccines, hosted an educational session on GSK’s Vaccines business at our manufacturing site in Wavre, Belgium on Thursday 26 September at 13:30 CET / 12:30 BST / 7:30 EDT.

Hal Barron, Chief Scientific Officer and President R&D, hosted a fireside chat at Goldman Sachs’ 40^th Annual Global Healthcare Conference, which took place in Rancho Palos Verdes, California on Wednesday 12 June, during which he has provided an update on the progress being made in GSK’s R&D organisation.

David Redfern, Chief Strategy Officer of GSK and Chairman of ViiV Healthcare, and Deborah Waterhouse, CEO of ViiV Healthcare, hosted a fireside chat at the Jefferies 2019 Healthcare Conference in New York on Thursday 6 June, during which they provided an update on the progress GSK and ViiV Healthcare have made this year.

Tobias Hestler, CFO GSK Consumer Healthcare, hosted a fireside chat at the Bernstein Consumer Healthcare & Nutrition Seminar in London on Tuesday 4 June during which he provided an update on the Consumer Healthcare business and the formation of a new, world-leading Consumer Healthcare joint venture.

David Redfern, Chairman ViiV Healthcare, Deborah Waterhouse, CEO ViiV Healthcare and Dr Kimberly Smith, VP Global Research & Medical Strategy hosted a ViiV Healthcare analyst call on Tuesday 30 April to discuss ViiV Healthcare’s recent regulatory activities and provide an update on the pipeline.

Luke Miels, President Global Pharmaceuticals, hosted a fireside chat at the Cowen & Co. 39th Annual Health Care Conference 2019 in Boston on Tuesday 12 March, during which he provided an update on the progress GSK is making in the global pharmaceuticals and vaccines business.

Brian McNamara, CEO GSK Consumer Healthcare, hosted a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference that took place in New York City on Thursday 28 February during which he provided an update on the Consumer Healthcare business and the formation of a new, world-leading Consumer Healthcare joint venture.

Axel Hoos, SVP Oncology R&D, hosted a Fireside Chat at the Guggenheim Healthcare Talks Idea Forum - Oncology Day held in New York City on Thursday 14 February during which he provided an update on GSK Oncology R&D progress.

Emma Walmsley, CEO, gave a presentation at the 37th annual JP Morgan Healthcare Conference in San Francisco on Tuesday 8 January, providing an overview of GSK’s priorities and the progress the company made during 2018.